SCHEMBL23358995

SCHEMBL23358995

O=C(O)[C@H]1C[C@@H](C(F)(F)F)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OAT P04181 1/20 0.38
CYP2C19 P33261 3/20 0.36
GABRR1 P24046 1/20 0.36
CYP2D6 P10635 3/20 0.34
CYP1A2 P05177 3/20 0.34
ALOX15 P16050 3/20 0.34
SLC1A3 P43003 1/20 0.34
SLC1A2 P43004 1/20 0.34
SLC1A1 P43005 1/20 0.34
GRM1 Q13255 2/20 0.34
TSHR P16473 2/20 0.33
PMP22 Q01453 2/20 0.33
ABAT P80404 2/20 0.33
APLNR P35414 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23358905 1.00 OAT (0.38) OATCYP2C19GABRR1CYP2D6CYP1A2
SCHEMBL4264726 1.00 OAT (0.38) OATCYP2C19GABRR1CYP2D6CYP1A2
SCHEMBL849491 0.97 OAT (0.41) OATCYP2C19GABRR1CYP2D6CYP1A2
SCHEMBL21057539 0.89 OAT (0.33) OATCYP2C19GABRR1GRM1
SCHEMBL21057288 0.89 OAT (0.33) OATCYP2C19GABRR1GRM1
SCHEMBL21057290 0.89 OAT (0.33) OATCYP2C19GABRR1GRM1
SCHEMBL28493088 0.83 ACE (0.39) OATCYP2C19GABRR1CYP2D6CYP1A2
SCHEMBL28405942 0.81 POLB (0.31) CYP2C19GRM1
SCHEMBL25250387 0.80 BTK (0.41) OATGABRR1TSHRPMP22GABRP
SCHEMBL849602 0.80 BTK (0.41) OATGABRR1TSHRPMP22GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 US disclosed
CN-118239937-A Compounds, compositions, and methods 戴纳立制药公司 2024-06-25 CN disclosed
CN-118239938-A Compounds, compositions, and methods 戴纳立制药公司 2024-06-25 CN disclosed
CN-111094233-B Compounds, compositions, and methods 戴纳立制药公司 2024-03-15 CN disclosed
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 US disclosed
US-20230083885-A1 MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY INTEGRAL BIOSCIENCES PVT. LTD. (IN) 2023-03-16 US disclosed
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. 2022-12-29 US disclosed
WO-2022212902-A1 MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. (US) 2022-10-06 WO disclosed
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2022-02-01 US disclosed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 US disclosed
CN-111094233-A Compounds, compositions and methods 戴纳立制药公司 2020-05-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 OAT 2276/4885CYP2C19 3892/4885GABRR1 2064/4885
US-20230083885-A1 MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, ATF1, DDIT3 OAT 1258/4885CYP2C19 4799/4885GABRR1 1178/4885
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 OAT 2276/4885CYP2C19 3892/4885GABRR1 2064/4885
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS EIF2B1, EIF4EBP1, EIF2B3 OAT 2069/4885CYP2C19 3737/4885GABRR1 1295/4885
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 OAT 2276/4885CYP2C19 3892/4885GABRR1 2064/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E OAT 2196/4885CYP2C19 2700/4885GABRR1 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.